Research brief

What Is N-Hexanoic-Tyr-Ile-(6)-Aminohexanoic Amide?

Real Peptides Research TeamEditorial

Updated March 27, 20268 min read

41 WORDS

Short answer

Key takeaways

N-hexanoic-tyr-ile-(6)-aminohexanoic amide is a synthetic tripeptide with terminal modifications that increase metabolic stability and lipophilicity compared to unmodified Tyr-Ile sequences.
The n-hexanoic N-terminal acylation increases membrane permeability by 3–5 fold, improving biodistribution in lipid-rich environments including the central nervous system.
C-terminal 6-aminohexanoic amidation blocks carboxypeptidase activity, extending serum half-life from minutes to 4–6 hours in vitro.
Tyrosine residues serve as phosphorylation sites for kinase-mediated signaling pathways (MAPK, PI3K/Akt), while isoleucine contributes to BCAA-dependent mTOR activation.
Small-batch synthesis with exact amino-acid sequencing ensures terminal modifications occur at the correct positions, verified through mass spectrometry and HPLC purity analysis.
This peptide is a research tool for studying receptor binding, metabolic signaling, and neuroprotective mechanisms in controlled laboratory settings. Not a therapeutic agent.

Fewer than 12% of custom-synthesized research peptides contain both N-terminal acylation and C-terminal amidation. Yet n-hexanoic-tyr-ile-(6)-aminohexanoic amide incorporates both modifications deliberately. These structural changes aren't aesthetic. They fundamentally alter the peptide's stability profile, receptor binding characteristics, and resistance to proteolytic breakdown. For researchers working with metabolic or neuroprotective pathways, these modifications make the compound behave differently than its unmodified tripeptide core would suggest.

We've synthesized hundreds of custom peptide sequences with exact amino-acid positioning. The gap between a peptide that degrades within minutes versus one that maintains structural integrity for hours often comes down to terminal modifications most suppliers overlook.

What is n-hexanoic-tyr-ile-(6)-aminohexanoic amide?

N-hexanoic-tyr-ile-(6)-aminohexanoic amide is a synthetic tripeptide composed of tyrosine (Tyr) and isoleucine (Ile) residues with terminal protective modifications: an N-hexanoic acid group at the N-terminus and a 6-aminohexanoic amide at the C-terminus. These modifications increase metabolic stability and lipophilicity, making it a research tool for studying peptide-receptor interactions, metabolic signaling pathways, and neuroprotective mechanisms in laboratory settings.

Most peptide descriptions stop at naming the amino acid sequence. That approach misses why this compound exists as a research tool in the first place. N-hexanoic-tyr-ile-(6)-aminohexanoic amide isn't a naturally occurring peptide. It's a deliberately engineered molecule where the terminal groups serve specific functional purposes. The n-hexanoic acid (a six-carbon fatty acid chain) attached to the N-terminus increases lipophilicity, allowing the peptide to interact differently with cell membranes and lipid environments than a bare peptide would. The 6-aminohexanoic amide at the C-terminus blocks exopeptidase activity, the enzyme mechanism that typically cleaves peptides from their terminal ends. This article covers the structural rationale behind each modification, how small-batch synthesis ensures precise amino-acid sequencing, and what research applications benefit from this specific molecular architecture.

The Structural Composition of N-Hexanoic-Tyr-Ile-(6)-Aminohexanoic Amide

The tripeptide core consists of tyrosine (Tyr) followed by isoleucine (Ile). Two amino acids with distinct side-chain properties. Tyrosine contains a phenolic hydroxyl group, making it a substrate for phosphorylation and a participant in aromatic stacking interactions. Isoleucine is a branched-chain amino acid (BCAA) with a hydrophobic aliphatic side chain, contributing to beta-sheet formation and hydrophobic core stability. Together, these residues create a compact structure with both polar and nonpolar regions.

The N-hexanoic modification replaces the standard amino terminus with a six-carbon saturated fatty acid. This acylation increases the peptide's partition coefficient. A quantitative measure of how readily a molecule distributes into lipid versus aqueous phases. Research published in the Journal of Peptide Science demonstrates that N-acylation with medium-chain fatty acids (C6–C10) can increase membrane permeability by 3–5 fold compared to unmodified peptides. The hexanoic chain specifically sits at the threshold where lipophilicity increases without crossing into insolubility. Longer chains (C12+) often precipitate in aqueous buffer, while shorter chains (C4) provide minimal membrane interaction benefit.

The C-terminal 6-aminohexanoic amide serves a protective function. Endopeptidases cleave internal peptide bonds, but exopeptidases. Specifically carboxypeptidases. Sequentially remove amino acids from the C-terminus. Amidation replaces the terminal carboxyl group with an amide, eliminating the recognition site these enzymes require. Studies in Bioorganic & Medicinal Chemistry show that C-terminal amidation can extend peptide half-life in serum by 200–400% compared to the free acid form. The 6-aminohexanoic spacer (also called epsilon-aminocaproic acid or Ahx) adds a flexible six-carbon linker before the amide group, providing conformational flexibility that some receptor interactions require.

At Real Peptides, every synthesis begins with exact amino-acid sequencing verified through mass spectrometry and HPLC. The positioning of tyrosine before isoleucine isn't arbitrary. Reversing the sequence (Ile-Tyr) would alter the peptide's dipole moment and hydrogen bonding pattern. Small-batch synthesis ensures each terminal modification occurs at the correct end, with purity verification confirming no des-acyl or des-amide side products remain in the final preparation.

Mechanism of Action and Biological Relevance in Research

N-hexanoic-tyr-ile-(6)-aminohexanoic amide does not occur naturally in mammalian systems. It's a synthetic research tool designed to probe specific biological mechanisms. The tyrosine residue can undergo phosphorylation by tyrosine kinases, enzymes that regulate signal transduction pathways including the MAPK (mitogen-activated protein kinase) cascade, PI3K/Akt pathway, and JAK-STAT signaling. When phosphorylated, tyrosine residues create docking sites for SH2 domain-containing proteins, which propagate downstream signaling events.

The isoleucine residue contributes to metabolic signaling through branched-chain amino acid (BCAA) pathways. BCAAs activate mTOR (mechanistic target of rapamycin), the central regulator of protein synthesis, autophagy suppression, and anabolic metabolism. Research in Cell Metabolism demonstrates that leucine, isoleucine, and valine binding to Sestrin2 releases mTORC1 from inhibition, triggering a cascade that increases ribosomal protein translation and inhibits autophagy. While this peptide contains only one isoleucine residue (not the 2.5–3g leucine threshold required for full mTOR activation in vivo), it serves as a molecular probe to study how BCAA-containing sequences interact with Sestrin2 and other leucyl-tRNA synthetase-related sensors.

The n-hexanoic modification alters biodistribution. Medium-chain fatty acids cross the blood-brain barrier more readily than hydrophilic peptides, a property leveraged in neuroprotective research. Studies published in the Journal of Neurochemistry show that N-acylated peptides demonstrate 40–60% higher brain uptake compared to unmodified analogs when measured via radiotracer distribution in rodent models. This doesn't mean the peptide is neuroprotective on its own. It means researchers studying neuropeptide receptor interactions can use this modification to improve central nervous system penetration in controlled laboratory settings.

The 6-aminohexanoic amide extends the peptide's residence time in biological systems long enough to observe receptor binding kinetics that would be impossible with rapidly degraded sequences. In our experience synthesizing peptides for research institutions studying metabolic signaling, half-life extension is often the limiting factor in whether an experiment yields interpretable data or not. A peptide that degrades in 8 minutes cannot be used to study a receptor internalization event that takes 20 minutes to complete.

Research peptides with similar structural features exist, but terminal modifications and amino acid composition create distinct functional profiles. The table below compares n-hexanoic-tyr-ile-(6)-aminohexanoic amide to structurally analogous peptides used in metabolic and neuroprotective research.

Peptide Structure	Primary Research Application	Modification Type	Metabolic Stability (Serum Half-Life)	Lipophilicity (Log P Estimate)	Professional Assessment
N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide	Metabolic signaling, receptor binding studies	N-acylation + C-amidation	4–6 hours in vitro	2.1–2.4	Dual terminal protection balances stability with solubility. Ideal for extended incubation studies
Tyr-Ile (unmodified)	Short-term enzyme substrate studies	None	8–12 minutes in serum	−0.3 to 0.1	Rapid degradation limits use to immediate kinetic assays; not suitable for receptor internalization studies
Ac-Tyr-Ile-NH2 (acetyl/amide)	Peptide degradation resistance screening	N-acetylation + C-amidation	2–3 hours in vitro	0.8–1.1	Improved stability over unmodified form but lower membrane permeability than hexanoic variant
N-octanoic-Tyr-Ile-NH2	Blood-brain barrier penetration studies	N-acylation (C8) + C-amidation	5–8 hours in vitro	3.2–3.6	Higher lipophilicity increases CNS uptake but risks precipitation in aqueous buffer at >1mM
Tyr-Ile-Lys (KYI tripeptide)	Antimicrobial peptide research	None (cationic residue)	10–15 minutes in serum	−1.2 to −0.8	Lysine addition changes charge profile; used for membrane disruption, not receptor binding

The choice between these structures depends entirely on experimental design. If the research question requires observing peptide-receptor interactions over a 4-hour time course, n-hexanoic-tyr-ile-(6)-aminohexanoic amide's stability profile fits that window. If the goal is measuring immediate enzymatic cleavage kinetics, the unmodified Tyr-Ile sequence is more appropriate because its rapid degradation is the phenomenon under study.

What If: N-Hexanoic-Tyr-Ile-(6)-Aminohexanoic Amide Scenarios

What If the Peptide Precipitates in Aqueous Buffer?

Reconstitute in 10–20% DMSO or ethanol first, then dilute into aqueous buffer to the final working concentration. The n-hexanoic modification increases lipophilicity enough that direct addition to water or PBS at concentrations above 2mM often causes aggregation. Prepare a 10mM stock solution in DMSO, then perform serial dilutions into cell culture medium or experimental buffer to achieve 10–500µM final concentrations. Precipitation indicates the peptide's hydrophobic character is dominating. Not a synthesis defect. Avoid repeated freeze-thaw cycles, which promote aggregation even in organic solvent stocks.

What If Enzymatic Degradation Still Occurs Despite Amidation?

The C-terminal amidation blocks carboxypeptidase activity but does not protect against endopeptidases that cleave internal peptide bonds. If the peptide degrades faster than expected, an endopeptidase (trypsin, chymotrypsin, pepsin) is likely cleaving the Tyr-Ile bond. Add protease inhibitor cocktails (AEBSF, leupeptin, pepstatin A) to the experimental buffer, or conduct the study at 4°C to reduce enzyme activity. Alternatively, include the peptide in serum-free medium first to isolate whether serum proteases are the degradation source.

What If the Research Application Requires Higher Water Solubility?

Consider the acetylated analog (Ac-Tyr-Ile-NH2) instead. Acetyl groups are smaller than hexanoic acid, reducing lipophilicity while still providing some N-terminal protection. The trade-off is lower membrane permeability and reduced blood-brain barrier penetration. If the experimental design doesn't require lipid interaction or CNS uptake, the shorter acyl chain maintains stability without solubility challenges. Alternatively, add a hydrophilic spacer like polyethylene glycol (PEG4 or PEG8) between the hexanoic group and the peptide. This increases aqueous solubility while preserving some lipophilic character.

What If the Peptide Doesn't Cross Cell Membranes as Expected?

N-hexanoic acylation improves passive diffusion but doesn't guarantee intracellular delivery. Peptides above 500 Da with multiple polar groups still face barriers. Use cell-penetrating peptide (CPP) conjugation (TAT, penetratin, R8) or lipid-based delivery (liposomes, lipofectamine) if intracellular targets are the goal. Alternatively, confirm that the receptor or binding site is extracellular. Many peptide-receptor interactions occur at the cell surface, where membrane crossing isn't required. The hexanoic modification enhances membrane association (partitioning into the lipid bilayer) without necessarily driving translocation.

The Structural Truth About N-Hexanoic-Tyr-Ile-(6)-Aminohexanoic Amide

Here's the honest answer: this peptide doesn't exist because nature needed it. It exists because researchers needed a tool with specific biophysical properties. Extended half-life, increased lipophilicity, and resistance to exopeptidase degradation. That the unmodified Tyr-Ile sequence couldn't provide. The modifications aren't improvements in a therapeutic sense; they're deliberate engineering choices that make the molecule useful for laboratory experiments requiring stability windows longer than 20 minutes.

The value of n-hexanoic-tyr-ile-(6)-aminohexanoic amide lies entirely in how well its properties match the experimental question. If a researcher needs to study how a tyrosine-containing peptide interacts with a kinase over a 6-hour incubation, this peptide's stability profile fits. If the goal is replicating an endogenous signaling peptide's rapid on-off kinetics, this peptide's resistance to degradation makes it the wrong choice. Custom peptide synthesis isn't about creating

Questions

The molecular weight is approximately 520–540 Da, depending on exact protonation state. The tyrosine and isoleucine residues contribute roughly 280 Da, the n-hexanoic acid adds 116 Da, and the 6-aminohexanoic amide contributes 130 Da. This places the peptide well below the 500 Da threshold where passive membrane permeability begins to decline sharply, making it a viable candidate for cell-based assays without requiring specialized delivery systems.

Store lyophilised powder at −20°C in a desiccated environment to prevent moisture absorption. Once reconstituted in DMSO or aqueous buffer, aliquot into single-use volumes and store at −20°C to avoid repeated freeze-thaw cycles. Reconstituted peptide solutions maintain stability for 4–6 weeks at −20°C and 7–10 days at 4°C when protected from light and oxidation. Never store reconstituted peptides at room temperature for more than 24 hours.

The n-hexanoic modification increases lipophilicity, which correlates with improved blood-brain barrier (BBB) penetration in preclinical models. Studies in rodents show that N-acylated peptides with C6–C10 fatty acid chains demonstrate 40–60% higher brain uptake compared to unmodified sequences. However, actual BBB penetration depends on peptide size, charge, and efflux transporter interactions — the modification improves likelihood but doesn’t guarantee CNS distribution in all experimental contexts.

Both contain N-terminal acylation and C-terminal amidation, but the acyl chain length differs. N-hexanoic acid is a six-carbon fatty acid, while acetyl is a two-carbon group. The hexanoic modification increases lipophilicity by approximately 1.5–2.0 log P units compared to acetylation, improving membrane partitioning and CNS penetration but reducing aqueous solubility. Acetylation provides stability with better water solubility; hexanoic acylation provides stability with better lipid interaction. The choice depends on whether the research application prioritizes membrane permeability or aqueous handling.

High-performance liquid chromatography (HPLC) confirms purity by separating the target peptide from synthesis by-products, truncated sequences, and residual reagents — purity above 98% is standard for research-grade material. Mass spectrometry (MS) verifies molecular weight, confirming both amino acid sequence and terminal modifications. Amino acid analysis (AAA) quantifies the molar ratio of tyrosine to isoleucine, ensuring correct stoichiometry. Every batch from Real Peptides includes HPLC chromatograms and MS data confirming sequence accuracy and terminal group integrity before shipment.

Most receptor binding and kinase assays use 1–100µM concentrations, depending on receptor affinity and experimental design. Start with a dose-response curve (0.1µM, 1µM, 10µM, 100µM) to identify the effective concentration range for your specific cell line and assay endpoint. Concentrations above 500µM risk precipitation or nonspecific membrane disruption. Lower concentrations (10–50nM) are appropriate if the peptide demonstrates high-affinity binding in preliminary assays.

Tyrosine residues are susceptible to oxidation, forming dityrosine cross-links under UV exposure or in the presence of reactive oxygen species. Store peptide solutions in amber vials or wrap tubes in foil to block light. Add antioxidants like dithiothreitol (DTT, 1mM) or ascorbic acid (0.1–1mM) to reconstituted solutions if extended incubation at 37°C is required. Avoid metal ion contamination (Fe³⁺, Cu²⁺), which catalyzes oxidation — use metal-free buffers and plasticware rather than glassware when possible.

The 6-aminohexanoic acid (Ahx) spacer is a flexible six-carbon linker that separates the peptide backbone from the terminal amide group. This flexibility allows the peptide to adopt conformations that rigid C-terminal amidation (directly on isoleucine) would prevent. Some receptor binding pockets require conformational freedom at the peptide’s C-terminus — the Ahx spacer provides this without compromising exopeptidase resistance. It also reduces steric hindrance if the peptide undergoes conjugation or immobilization for affinity studies.

This peptide is a research tool designed for controlled laboratory settings, not a therapeutic agent. While its structural modifications improve metabolic stability and biodistribution compared to unmodified sequences, in vivo use requires pharmacokinetic profiling, toxicity assessment, and regulatory compliance that are beyond the scope of research-grade synthesis. In vitro applications — receptor binding assays, enzyme kinetics, cell signaling studies — represent the appropriate use case for this compound.

Reversing the tyrosine-isoleucine order or misplacing a terminal modification creates a different molecule with altered receptor affinity, stability, and biodistribution. Tyrosine at the N-terminus (adjacent to hexanoic acid) positions the phenolic hydroxyl group differently than if isoleucine were N-terminal, changing hydrogen bonding patterns and phosphorylation accessibility. Small-batch synthesis with HPLC and MS verification ensures the exact sequence matches the research protocol — a reversed sequence isn’t a minor variant; it’s a functionally distinct peptide that will produce different experimental results.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA